Jiangsu Hanbon Science and Technology
688755
ZERUN CO., LTD
301636
SENXUAN
830946
4
Greenworks
301260
5
Tuoxin Pharmaceutical Group
301089
CN Stock MarketDetailed Quotes
603858 Shandong Buchang Pharmaceuticals
- 16.08
- +0.19+1.20%
Market Closed May 16 15:00 CST
17.79BMarket Cap-49.33P/E (TTM)
16.11High15.90Low62.91KlotVolume15.98Open15.89Pre Close100.75MTurnover0.57%Turnover RatioLossP/E (Static)1.11BShares19.7052wk High1.70P/B17.79BFloat Cap13.8352wk Low17.48Limit Up1.11BShs Float86.04Historical High14.30Limit Down1.32%Amplitude13.36Historical Low0.13Dividend TTM16.02Avg Price25.92KlotAsk0.78%Div YieldTTM100Lot Size35.85KlotBid
Shandong Buchang Pharmaceuticals Key Stats
All
YOY
| (Q3)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 5.47%2.78B | -16.91%11.01B | -14.71%8.51B | -21.93%5.43B | -24.88%2.64B | -11.41%13.25B | -11.69%9.98B | -1.98%6.96B | 9.83%3.51B | -5.15%14.95B |
| Operating revenue | 5.47%2.78B | -16.91%11.01B | -14.71%8.51B | -21.93%5.43B | -24.88%2.64B | -11.41%13.25B | -11.69%9.98B | -1.98%6.96B | 9.83%3.51B | -5.15%14.95B |
| Other operating revenue | ---- | 92.93%32.06M | ---- | -1.48%7.24M | ---- | 72.81%16.62M | ---- | 82.88%7.35M | ---- | --9.62M |
| Total operating cost | -0.40%2.46B | -15.03%10.39B | -12.17%7.98B | -19.36%5.06B | -20.38%2.47B | -7.73%12.23B | -9.34%9.08B | -1.13%6.28B | 7.93%3.11B | -6.34%13.25B |
| Operating cost | -2.53%1.06B | 4.96%4.43B | 16.68%3.65B | 7.18%2.34B | 2.79%1.09B | -0.34%4.22B | -7.86%3.13B | -5.40%2.18B | 20.35%1.06B | 2.41%4.23B |
| Operating tax surcharges | 9.88%44.73M | -26.16%159.02M | -23.97%122.82M | -34.04%73.79M | -28.87%40.71M | -7.20%215.36M | -4.29%161.54M | 3.03%111.86M | 10.62%57.24M | 2.28%232.07M |
| Operating expense | 2.56%1.09B | -32.12%4.32B | -32.42%3.27B | -38.78%2.07B | -37.91%1.06B | -14.90%6.37B | -11.64%4.84B | 1.44%3.38B | 4.52%1.71B | -9.83%7.48B |
| Administration expense | -6.03%192.31M | 1.43%1.01B | -9.98%664.11M | -14.47%405.88M | -8.57%204.65M | 10.36%995.94M | 13.28%737.73M | 6.65%474.56M | -1.84%223.84M | -3.67%902.46M |
| Financial expense | -1.01%27.47M | 33.94%122.78M | 38.82%89.98M | 63.23%59.38M | 85.01%27.75M | -19.26%91.66M | -29.10%64.81M | -44.31%36.38M | -53.77%15M | -19.30%113.53M |
| -Interest expense (Financial expense) | -2.09%28.74M | 17.88%129.59M | 11.67%94.77M | 19.05%62.56M | 11.72%29.35M | -18.63%109.93M | -19.69%84.87M | -27.87%52.55M | -38.24%26.27M | -19.24%135.1M |
| -Interest Income (Financial expense) | 13.65%-1.59M | 60.02%-7.53M | 74.83%-5.56M | 79.47%-3.58M | 84.84%-1.84M | 5.28%-18.82M | -45.88%-22.11M | -108.56%-17.45M | -48.06%-12.15M | 16.24%-19.87M |
| Research and development | -1.90%45.15M | 3.08%345.41M | 19.33%180.2M | 21.66%122.03M | 24.93%46.02M | 17.94%335.08M | -35.93%151.01M | 0.75%100.3M | -20.03%36.84M | -30.47%284.12M |
| Credit Impairment Loss | 1.87%26.44M | 230.40%22.59M | 33.09%17.92M | 276.54%28.18M | 4,902.47%25.95M | -1.11%-17.32M | 767.64%13.46M | 49.19%7.48M | -95.17%518.84K | 31.02%-17.13M |
| Asset Impairment Loss | 1,909.78%2.31M | -39.50%-977.51M | -1,511.27%-28.06M | -135.70%-22.29M | -109.95%-127.87K | 76.91%-700.72M | -136.23%-1.74M | -296.76%-9.46M | -72.45%1.29M | -2,089.12%-3.04B |
| Other net revenue | 33.59%61.57M | -48.02%-864.34M | -73.15%59.44M | -78.73%42.63M | -58.28%46.09M | 80.22%-583.94M | -16.34%221.38M | -19.71%200.42M | -47.06%110.47M | -73,138.12%-2.95B |
| Fair value change income | 206.00%2.08M | 93.66%-149.33K | 33.80%-779.84K | -350.70%-2.95M | ---1.96M | ---2.36M | ---1.18M | --1.18M | ---- | ---- |
| Invest income | 71.34%-608.27K | -38.85%13.02M | -58.14%7.47M | -83.36%3.22M | -131.51%-2.12M | 678.38%21.29M | 50.87%17.85M | 101.85%19.37M | 328.79%6.74M | -84.47%2.74M |
| -Including: Investment income associates | 104.15%80.91K | 44.30%14.86M | 49.35%6.34M | -38.40%5.03M | -170.90%-1.95M | 1,023.70%10.3M | 4.70%4.25M | 55.83%8.17M | 159.88%2.75M | -108.85%-1.12M |
| Asset deal income | 12,960.27%161.55K | -72.06%427.42K | -96.31%23.48K | 109.50%33.87K | 115.34%1.24K | 97.84%1.53M | 12,307.58%636.51K | 397.38%16.17K | 71.34%-8.06K | -53.93%773.1K |
| Other revenue | 28.12%31.19M | -31.98%77.29M | -67.32%62.87M | -79.96%36.43M | -76.12%24.34M | 17.14%113.63M | -23.07%192.35M | -21.01%181.82M | -48.05%101.94M | -53.42%97M |
| Operating profit | 79.62%382.81M | -156.59%-246.75M | -46.91%594.91M | -53.32%409.58M | -58.91%213.13M | 134.90%436.02M | -27.66%1.12B | -11.83%877.39M | -2.27%518.68M | -177.10%-1.25B |
| Add:Non operating Income | 282.66%1.28M | -37.17%4.92M | 11.24%2.86M | 55.96%1.97M | -56.20%334.02K | 74.59%7.84M | 24.28%2.57M | 6.32%1.27M | -62.46%762.63K | 81.83%4.49M |
| Less:Non operating expense | 160.30%7.96M | 150.43%123.46M | 126.43%95.92M | -47.26%7.58M | -37.61%3.06M | 241.92%49.3M | 272.47%42.36M | 74.52%14.37M | -26.13%4.9M | -60.47%14.42M |
| Total profit | 78.77%376.13M | -192.58%-365.29M | -53.57%501.85M | -53.26%403.97M | -59.11%210.4M | 131.33%394.56M | -29.81%1.08B | -12.53%864.29M | -2.20%514.54M | -179.38%-1.26B |
| Less:Income tax cost | -29.72%86.24M | 38.90%337.1M | 13.78%283.97M | 23.32%222.84M | 56.10%122.7M | -26.81%242.69M | -20.91%249.57M | -11.53%180.71M | -31.83%78.6M | -30.67%331.59M |
| Add:Adjusted items effecting net profit | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0.01 | ---- | ---- |
| Net profit | 230.55%289.89M | -562.51%-702.39M | -73.79%217.88M | -73.50%181.14M | -79.88%87.7M | 109.55%151.87M | -32.10%831.23M | -12.79%683.58M | 6.12%435.94M | -243.55%-1.59B |
| Net profit from continuing operation | 230.55%289.89M | -562.51%-702.39M | -73.79%217.88M | -73.50%181.14M | -79.88%87.7M | 109.55%151.87M | -32.10%831.23M | -12.79%683.58M | 6.12%435.94M | -243.55%-1.59B |
| Less:Minority Profit | 33.99%-17.37M | 11.08%-148.6M | -1.15%-94.99M | 19.62%-50.28M | -36.14%-26.32M | -172.88%-167.11M | -120.45%-93.91M | -80.95%-62.56M | -1.53%-19.33M | -13.75%-61.24M |
| Net profit of parent company owners | 169.49%307.26M | -273.62%-553.8M | -66.18%312.86M | -68.98%231.42M | -74.96%114.02M | 120.85%318.97M | -26.97%925.14M | -8.83%746.14M | 5.91%455.27M | -231.63%-1.53B |
| Add:Adjusted items effecting net profit of parent company owners | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0.01 | ---- | ---- |
| Earning per share | ||||||||||
| Basic earning per share | 180.10%0.2899 | -277.18%-0.511 | -65.69%0.287 | -68.72%0.211 | -74.85%0.1035 | 120.85%0.2884 | -26.98%0.8364 | -8.83%0.6746 | 5.92%0.4116 | -231.64%-1.3831 |
| Diluted earning per share | 180.10%0.2899 | -277.18%-0.511 | -65.69%0.287 | -68.72%0.211 | -74.85%0.1035 | 120.85%0.2884 | -26.98%0.8364 | -8.83%0.6746 | 5.92%0.4116 | -231.64%-1.3831 |
| Other composite income | -359.46%-935.56K | -102.76%-605.75K | 87.18%-68.69K | 41.17%-349.03K | 91.25%-203.62K | 95.83%-298.75K | 94.21%-535.91K | 92.51%-593.32K | -19.97%-2.33M | -138.12%-7.16M |
| Other composite income of parent company owners | -359.46%-935.56K | -102.76%-605.75K | 87.18%-68.69K | 41.17%-349.03K | 91.25%-203.62K | 95.83%-298.75K | 94.21%-535.91K | 92.51%-593.32K | -19.97%-2.33M | -138.12%-7.16M |
| Add:Adjusted items effecting composite income | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---0.01 | ---- | ---- |
| Total composite income | 230.25%288.95M | -563.82%-703M | -73.78%217.81M | -73.53%180.79M | -79.82%87.5M | 109.48%151.57M | -31.63%830.7M | -11.97%682.99M | 6.05%433.61M | -241.80%-1.6B |
| Total composite income of parent company owners | 169.15%306.33M | -273.97%-554.4M | -66.17%312.79M | -69.01%231.07M | -74.87%113.81M | 120.73%318.67M | -26.48%924.61M | -8.01%745.54M | 5.85%452.94M | -230.15%-1.54B |
| Total composite income of minority owners | 33.99%-17.37M | 11.08%-148.6M | -1.15%-94.99M | 19.62%-50.28M | -36.14%-26.32M | -172.88%-167.11M | -120.45%-93.91M | -80.95%-62.56M | -1.53%-19.33M | -13.75%-61.24M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
| Auditor | -- | Shinaga Zhonghe Certified Public Accountants Co., Ltd. (Special General Partnership) | -- | -- | -- | Shinaga Zhonghe Certified Public Accountants Co., Ltd. (Special General Partnership) | -- | -- | -- | Shinaga Zhonghe Certified Public Accountants Co., Ltd. (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.